Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

Among more than 350 patients with stage II-IIIB disease, rates of MPR reached 26% with osimertinib and chemotherapy combined and 25% with single-agent osimertinib, as compared with 2% in the ...

SAN DIEGO — Combination therapy with osimertinib and savolitinib could become a novel first-line treatment option for patients with de novo MET-aberrant, EGFR-mutated advanced non–small cell ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EG ...

CHICAGO — Osimertinib (Tagrisso) may soon have approvals across all stages of epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC). The third-generation EGFR ...

Patients with stage IB to IIIA non-small cell lung cancer that received osimertinib after surgery had a 51% lower risk of death compared to placebo. OS benefit observed across all predefined ...

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy. FDA has approved the targeted therapy osimertinib (Tagrisso ...

Patients with EGFR-mutated NSCLC who received osimertinib had an elevated risk for therapy-related cardiac events. Cardiac events were independently associated with survival. Patients with EGFR ...